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The odorous steroid androstadienone, a putative male chemo-signal, was previously
reported to evoke sex differences in hypothalamic activation in adult heterosexual men and
women. In order to investigate whether puberty modulated this sex difference in response
to androstadienone, we measured the hypothalamic responsiveness to this chemo-signal
in 39 pre-pubertal and 41 adolescent boys and girls by means of functional magnetic reso-
nance imaging. We then investigated whether 36 pre-pubertal children and 38 adolescents
diagnosed with gender dysphoria (GD; DSM-5) exhibited sex-atypical (in accordance with
their experienced gender), rather than sex-typical (in accordance with their natal sex) hypo-
thalamic activations during olfactory stimulation with androstadienone. We found that the
sex difference in responsiveness to androstadienone was already present in pre-pubertal
control children and thus likely developed during early perinatal development instead of dur-
ing sexual maturation. Adolescent girls and boys with GD both responded remarkably like
their experienced gender, thus sex-atypical. In contrast, pre-pubertal girls with GD showed
neither a typically male nor female hypothalamic activation pattern and pre-pubertal boys
with GD had hypothalamic activations in response to androstadienone that were similar to
control boys, thus sex-typical. We present here a unique data set of boys and girls diag-
nosed with GD at two different developmental stages, showing that these children possess
certain sex-atypical functional brain characteristics and may have undergone atypical sexual
differentiation of the brain.
Keywords: androstadienone, chemo-signal, fMRI, gender dysphoria, hypothalamus, puberty, sex difference
INTRODUCTION
In humans, the odorous steroid 4,16-androstadien-3-one
(androstadienone) has been studied intensively as a putative
male modulator chemo-signal. Androstadienone, probably syn-
thesized in the gonads (1), is secreted by the apocrine glands
and can be found on the skin surface and axillary hairs (2), as
well as in several body fluids including sweat and semen (3, 4).
Higher concentrations of androstadienone in sweat have been
found in men compared to women (5, 6). Exposure to androsta-
dienone has been shown to affect women’s mental state (7–10),
and to elicit physiological responses in a sex-dependent manner
(7, 9, 11–15). Moreover, smelling androstadienone had an impact
on women’s hormone levels (16) and affected their behavioral
responses dependent on the phase of the menstrual cycle (17).
In line with the effects androstadienone had on the autonomic
nervous system and on behavior, studies conducted by Savic et al.
(18), using positron emission tomography (PET), showed that
smelling androstadienone induced a response in the hypothala-
mus of heterosexual women but not in heterosexual men. The
latter only showed an activation in brain areas belonging to the
main olfactory system, such as the piriform cortex and amygdala
(18). Thus, olfactory stimulation with androstadienone offers a
relatively simple and objective experimental procedure for inves-
tigating functional sex differences in the human brain. Using
functional magnetic resonance imaging (fMRI), we recently repli-
cated the finding of women showing a stronger hypothalamic
activation than men, after smelling the highest (10 mM) out of
three concentrations tested (19).
Secretion of androstadienone increases substantially during
puberty. As a result, sex-related changes in olfactory sensitivity to
androstenes have been reported during adolescence (20–23) with
male adolescents exhibiting more anosmia to androstadienone,
and an increase of odor threshold with age, compared to female
adolescents. It may be inferred that the decrease in sensitivity to
odorous steroids in pubescent boys is related to their increased
production of endogenous androgens during puberty, probably
reflecting adaptation toward (male) body odors.
Sisk and colleagues (24, 25) proposed a two-stage model of sex-
ual differentiation of brain and behavior, in which early perinatal
organizational effects of steroid hormones are followed by a second
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steroid-dependent sensitive phase of neurodevelopment during
adolescence. Thus, puberty may be considered an organizational
period in itself, in which sex differences in brain morphology and
function are established or consolidated. Therefore, our first aim
was to investigate whether the hypothalamic response to androsta-
dienone develops during puberty, as part of sexual maturation,
or whether it would already be present in pre-pubertal children
and thus established during early brain development. Thus, we
tested whether the response to androstadienone varied as a func-
tion of sex and pubertal status in four groups of pre-pubertal and
adolescent boys and girls.
Of note, further studies by Savic et al. (26–28) showed that
hypothalamic activation upon exposure to androstadienone also
depended on sexual orientation (27, 28) and gender identity. Adult
men diagnosed with gender dysphoria (GD) [DSM-5, Ref. (29)],
and thus having a female gender identity showed a sex-atypical
hypothalamic response, which reflected more on their experienced
gender than their natal sex (26). This is in line with the hypothe-
sis that individuals, diagnosed with GD might have undergone a
sex-atypical programing of the nervous system (30, 31). The etiol-
ogy of GD is currently unknown, however, a multitude of factors,
ranging from adverse psycho-dynamic parent–child interactions
(32), an anxious personality predisposition (33), genetic risk fac-
tors (34), and exposure to atypical levels of perinatal sex steroids
during a critical period of sexual differentiation of the brain (35)
have all been proposed to facilitate the development of GD.
At the Center of Expertise on Gender Dysphoria in Amsterdam,
the current treatment protocol allows adolescents diagnosed with
GD that persisted from childhood into adolescence to start treat-
ment with gonadotropin-releasing hormone analogs (GnRHa)
from the age of 12 years, to suppress endogenous gonadal stimu-
lation and thus the development of irreversible sex characteristics
of the natal sex (36). From the age of 16 years on, as a first step
in sex reassignment they receive cross-sex hormone treatment,
i.e., biological boys receive estrogens and biological girls receive
androgens (37, 38).
A second aim of the current study was therefore to explore
whether children and adolescents, diagnosed with GD, would show
brain responses that reflect their expressed/experienced gender
rather than their natal sex, and whether these would vary as a
function of their developmental phase. Four groups of subjects,
all diagnosed with GD, participated in the current study: girls and
boys that were pre-pubertal and treatment-naïve, and girls and
boys that were adolescent in age (though in hypogonadal state due
to GnRHa treatment). None of our participants received cross-sex
hormones at the time of data acquisition.
MATERIALS AND METHODS
SUBJECTS
The initial study sample consisted of a total of 158 participants.
Four subjects were excluded from further analysis, because of
anatomical anomalies (one adolescent), technical errors during
data collection (one child), or because the diagnosis GD had been
revised since their participation in the study (two boys with GD in
remission). All participants diagnosed with GD, were recruited via
the Center of Expertise on Gender Dysphoria at the VU Univer-
sity Medical Center in Amsterdam. The control participants were
recruited via several primary and secondary schools in the Nether-
lands and by inviting friends and relatives of the participants
with GD.
The children sample consisted of 19 control girls [mean years
of age (M )= 9.7, standard deviation (SD)= 0.9], 20 control boys
(M = 9.5, SD= 1.1), 17 girls with GD (M = 9.6, SD= 1.1), and
19 boys with GD (M = 10.4, SD= 0.9). All children underwent a
short physical examination by a pediatric endocrinologist (Daniel
T. Klink) in order to ascertain their pre-pubertal status (Tanner
stage 1) (39, 40).
The adolescent groups consisted of 21 control girls (M = 16.3,
SD= 0.9), 20 control boys (M = 15.0, SD= 0.6), 21 girls with
GD (M = 16.1, SD= 0.8), and 17 boys with GD (M = 15.3,
SD= 1.2). The adolescent participants, diagnosed with GD, had
been treated monthly with 3.75 mg of Triptorelin (Decapeptyl-
CR®, Ferring, Hoofddorp, the Netherlands) by injection for on
average 24 months (range 2-48 months), resulting in complete
suppression of gonadal hormone production. Female adoles-
cent controls were tested randomly according to their menstrual
cycle and 11 out of 21 control girls reported using hormonal
contraception.
ASSESSMENTS AND SUBJECT CHARACTERISTIC
Sexual orientation was difficult to assess, especially in the pre-
pubertal sample, because most children were simply too young to
be able to report their sexual orientation. Therefore, current or
presumed future sexual attraction was assessed by asking whether
the participant had ever been in love with somebody, and if yes,
whether that person was a boy or a girl. Normal olfactory func-
tion was ascertained by means of an extended version of the
“Sniffin’ Sticks” test battery (32-item odor identification test and
olfactory threshold measurement) (41–43). Furthermore, partic-
ipants were asked to report the perceived intensity of a 10 mM
androstadienone solution (on a scale from 0 to 10). Separately,
for the adolescent and the children samples, one-way analyses of
variance (ANOVA) were conducted, using the Statistical Package
for the Social Sciences, version 20 (SPSS Inc., Chicago, IL, USA),
testing whether the four gender groups differed on any of these
measures. Bonferroni correction for multiple comparisons was
applied for post hoc tests, considering a threshold of p< 0.05 as
statistically significant. All subjects and their legal guardians gave
their informed consent according to the Declaration of Helsinki,
and the study was approved by the Ethics Committee of the
VU University Medical Center Amsterdam (application number
NL31283.029.10).
OLFACTORY STIMULATION
Androstadienone (Steraloids Inc., Newport, RI 02840, USA) was
diluted in propylene glycol (Sigma) to a concentration of 10 mM,
according to the “high” concentration used in our previous study
(19). The volume of the solution used during the fMRI experi-
ments was 20 ml. Olfactory stimuli were delivered through a tubing
system to the subjects’ nostrils by means of a custom-built air-
dilution olfactometer [for details of the olfactometer set-up and
procedure see Ref. (19)]. With a total air flow of about 1 L/min,
during “ON” periods every 2 s, the odor was delivered during 1 s,
while during “OFF” periods subjects received odorless air.
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IMAGE ACQUISITION
Scans were performed on a 3.0-T GE Signa HDxt scanner (Gen-
eral Electric, Milwaukee, WI, USA). A gradient echo, echo planar
imaging sequence was used for functional imaging (19.2 cm2 field
of view, TR of 1950 ms, TE of 25 ms, an 80° flip angle, isotropic
voxels of 3 mm, and 36 slices). Before each imaging session, a local
high-order shimming technique was used to reduce susceptibility
artifacts. A scanning session consisted of six alternating ON-OFF
cycles over 108 volumes in a classical block design (one block
consisted of nine volumes), lasting 3.6 min. For co-registration
with the functional images, a T1-weighted scan was obtained (3D
FSPGR sequence, 25 cm2 field of view, TR of 7.8 ms, TE of 3.0 ms;
slice thickness of 1 mm, and 176 slices).
IMAGE PROCESSING
Data analysis was performed with SPM8 software (Statistical Para-
metric Mapping; Wellcome Department of Imaging Neuroscience,
Institute of Neurology at the University College London, UK)
implemented in Matlab R2009b (Math Works Inc., Natick, MA,
USA). Functional images were slice-timed and realigned to the
mean image, followed by unwarp. Applying the “New Segment”
and “Create Template” options of the DARTEL (Diffeomorphic
Anatomical Registration Through Exponentiated Lie Algebra)
toolbox, structural images were segmented. Then, gray matter
and white matter images were used for creating age-group spe-
cific templates (one for the children and the adolescents sample
each), registered in Montreal neurological institute (MNI) space.
Functional images were spatially normalized to their respective
group-template, applying each individual’s DARTEL flow field,
and finally, images were smoothed by means of a 5-mm full width
half maximum (FWHM) isotropic Gaussian kernel.
Individual image data were analyzed using boxcar regressors
convolved with a synthetic hemodynamic response function and
a first-order time-modulation (TM) regressor to test for possible
effects of adaptation/sensitization to androstadienone. In order to
account for assumed late “wash-out” effects during OFF blocks
and an early peak response to the odor stimulation during ON
blocks, first-level contrast images were built by subtracting the sec-
ond half (b) of the OFF blocks (four volumes) from the first part
(a) of the ON blocks (four volumes). Accordingly, this was done
with the associated TM regressor blocks. Further, based on the
image realignment process, individual head jerks were identified
(>1 mm displacement) (44). Together with the six motion para-
meters, these so-called scan nulling regressors were included in
every first-level design matrix to account for the effects of excessive
head motion.
STATISTICAL ANALYSES
First, in order to test whether the sex difference in response
to androstadienone was present in both developmental control
groups, and whether that sex difference in responsiveness varied as
a function of adaptation/sensitization to the odor, we conducted
a sex (control boys, control girls) by odor stimulation ANOVA,
for both the pre-pubertal and the adolescent control groups.
The factor odor stimulation consisted of two levels, a regressor
modeling the condition ONa-OFFb effect, thus the hypothesized
hypothalamic response to the odor, and a first-order parametric
modulation TM ONa-TM OFFb regressor, which signifies how
well the hypothalamic response correlates with changes over time,
thus modeling possible effects of adaptation or sensitization.
Second, by means of four gender by odor stimulation ANOVAs
separately for the pre-pubertal and the adolescent groups, we
tested whether boys and girls diagnosed with GD differed sig-
nificantly in response to the steroid odor in comparison to their
respective natal sex or their experienced gender control group.
Analyses were restricted to the hypothalamus area as region
of interest (ROI), defined [with Marsbar (45)] as a sphere (cen-
tered at MNI coordinates x = 0, y = -10, z = -7; with a 7-mm
radius), and based on anatomical demarcations following (46)
and (47). The threshold for statistical significance was set at
p< 0.05 family-wise error (FWE)-corrected for the extent of the
hypothalamus ROI.
RESULTS
PSYCHOPHYSICS AND SUBJECT CHARACTERISTICS
Demographic, self-report, and subject characteristics are pre-
sented in Table 1. The adolescent boys with GD were significantly
younger and less physically mature than the three other adoles-
cent groups. The pre-pubertal boys with GD were significantly
older than the pre-pubertal control boys. Therefore, in all group
comparisons involving boys with GD, age was included as covari-
ate. As expected, both adolescent control groups differed signifi-
cantly from the boys and girls diagnosed with GD with respect to
reported sexual orientation. There were no group differences in
olfactory performance and on ratings of the perceived intensity of
androstadienone.
SEX DIFFERENCES IN HYPOTHALAMIC ACTIVATION – EFFECTS OF
PUBERTY
In order to determine whether hypothalamic activation upon
smelling androstadienone is dependent on puberty, we conducted
separate ANOVAs in the pre-pubertal and the adolescent groups,
and compared hypothalamic activation in control girls to that
of control boys during exposure to androstadienone. Results are
displayed in Table 2.
Pre-pubertal girls and boys did not differ in terms of gen-
eral hypothalamic responsiveness (condition effect ON>OFF) to
androstadienone, but directional t -tests showed that the sex differ-
ence (girls> boys) was significantly modulated by the effect of the
TM regressor (t = 3.3; p= 0.033), indicating that hypothalamic
activation in boys differed from that of the girls during the course
of the scanning session, thus suggesting differences in adaptation
and/or sensitization to the odor between groups (see Figures 1A
and 2A,C).
Accordingly, similar comparisons were done in the adoles-
cent groups. Again, the sex difference in hypothalamic activa-
tion (girls> boys) was significantly dependent on the factor time
(t = 3.5; p= 0.019) (see Figures 1B and 3A,D). Visual inspection
of the data (see Figure 1) revealed that control girls’ activation
increased with repeated exposure to androstadienone (sensitiza-
tion), particularly toward the end of the session, whereas control
boys’ responsiveness to the steroid odor seemed relatively stable,
showing a slight decrease in activation during the course of the
stimulation session.
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Table 2 | ANOVA results showing sex differences in hypothalamus
activations in the control groups, and sex-atypical hypothalamic
activations, reflecting their experienced gender, in individuals with
GD.
Effect Zmax x y z N PFWE
CTRL GIRLS>CTRL BOYS
Children Gender 2.5 -6 -12 -5 30 0.202
Odor 2.4 -2 -15 -2 39 0.244
ON-OFF 1.8 0 -10 -14 1 0.456
ONTM-OFFTM 3.2 -6 -12 -5 92 0.033
2.9 6 -7 -8
Adolescents Gender 1.7 -3 -7 -2 17 0.091
Odor 1.7 6 -7 -6 8 0.655
ON-OFF 3.4 6 -7 -8 1 0.522
ONTM-OFFTM 2.5 -6 -12 -5 115 0.019
CTRL GIRLS>GIRLS WITH GD
Children No effects
Adolescents Gender 3.5 6 -7 -9 76 0.016
Odor 1.7 -6 -7 -6 1 0.627
ON-OFF – – – – – –
ONTM-OFFTM 4.1 6 -7 -9 214 0.002
BOYS WITH GD>CTRL BOYS
Children Gender 1.8 2 -14 -2 4 0.447
Odor 1.9 0 -10 0 3 0.436
ON-OFF 1.7 -4 -6 -4 12 0.437
ONTM-OFFTM 1.9 0 -10 -12 31 0.329
2.4 0 -14 -12
Adolescents Gender 2.2 6 -8 -6 11 0.237
Odor 3.0 0 -14 -12 1 0.341
ON-OFF 1.8 2 -14 -2 36 0.046
ONTM-OFFTM – – – – – –
BOYS WITH GD>GIRLS WITH GD
Children No effects
Adolescents Gender – – – – – –
Odor 1.9 3 -12 -9 12 0.535
ON-OFF – – – – – –
ONTM-OFFTM 2.1 3 -10 -2 26 0.323
Ctrl, control; GD, gender dysphoria; Zmax, z-value of peak activation voxel; x y z,
coordinates in Montreal Neurological Institute (MNI) space; N, number of cluster-
ing voxels (cluster size); FEW, family-wise error; the effects “Gender” and “Odor”
indicate omnibus F-contrasts for the factors gender and odor stimulation; “ON-
OFF” and “ONTM-OFFTM” indicate directional t-contrasts for the condition effect
and the first-order time-modulation regressor, respectively. Bold font indicates
statistically significant effects.
GENDER IDENTITY AND HYPOTHALAMIC ACTIVATION
In order to test whether individuals diagnosed with GD would
show a hypothalamic activation that reflected their experienced
gender, and whether this brain response would be different for pre-
pubertal and adolescent subjects, four ANOVAs were conducted,
in which control girls were compared to girls with GD, and control
boys were compared to boys with GD (see Table 2). In addition,
we investigated the reverse effects, i.e., whether individuals with
GD showed sex-typical activations, and thus deviated from their
experienced gender by comparing girls with GD to control boys,
and boys with GD to control girls (see Table 3). Comparing girls
with GD to boys with GD revealed no significant differences, thus
the sex difference in response to androstadienone observed in the
control groups was absent in the groups diagnosed with GD.
Girls diagnosed with GD
None of the comparisons between pre-pubertal control girls and
pre-pubertal girls with GD revealed any differences in hypothala-
mic activation upon smelling androstadienone. However, no sex-
typical effects (i.e., a female-typical hypothalamus response),when
compared to control boys, could be confirmed. Thus, pre-pubertal
girls with GD neither differed significantly from their experienced
(control boys) nor from their natal sex (control girls) in terms of
hypothalamic activation when smelling androstadienone.
In contrast, the comparison of adolescent control girls to
girls diagnosed with GD revealed a significant effect of gender
(control girls> girls with GD), which was mainly explained by
the effect of the TM regressor (t = 4.3; p= 0.002) (see Table 2;
Figures 3B,E). Thus, control girls showed a significantly stronger
hypothalamic response to androstadienone over time as described
earlier, whereas the activation in girls with GD, similar to ado-
lescent control boys, remained stable throughout the scanning
session. The reverse group comparisons (girls with GD> control
boys) revealed no significant effects (see Figure 3F), indicating
that adolescent girls with GD showed no hypothalamic activa-
tion upon smelling androstadienone as was observed in adolescent
control boys.
Boys diagnosed with GD
No significant effects were revealed when comparing pre-pubertal
boys with GD with control boys. In contrast, a significant effect
of gender, driven by the TM regressor (t = 3.5; p= 0.013 FWE-
corrected) was revealed when comparing pre-pubertal boys with
GD to control girls, indicating that pre-pubertal boys with GD
showed a pattern of hypothalamic activation that was similar to
that of the pre-pubertal control boys (see Table 3; Figures 2B,D,E).
When adolescent boys with GD were compared to adoles-
cent control boys we observed a significant effect of condition
(ON>OFF) (t = 1.8; p= 0.046) (see Table 2; Figures 3C,G,H).
Thus, adolescent boys with GD showed a significantly stronger,
thus sex-atypical response to androstadienone compared to con-
trol boys, irrespective of the factor time. The reverse contrast
(control girls> adolescent boys with GD), i.e., testing whether
adolescent boys with GD would show an activation according to
their natal sex, revealed no significant activations. Thus, adoles-
cent boys with GD showed female-typical hypothalamic responses
upon smelling androstadienone without, however, any effects due
to sensitization.
DISCUSSION
SEX DIFFERENCES IN HYPOTHALAMIC ACTIVATION – EFFECTS OF
PUBERTY
The present study is, to our knowledge, the first to demon-
strate that sex differences in hypothalamic activation upon
smelling androstadienone are already present before puberty, and
thus may be considered as a sex difference established during
early brain development. We found that pre-pubertal as well as
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FIGURE 1 |The mean percent signal change for the hypothalamic region
of interest during the course of the scanning session in the control
groups. (A) Shows the responses in the pre-pubertal boys and girls; (B) shows
the changes in activation over time in the adolescent control groups. Numbers
1–6 indicate the six time bins of the odor stimulation block design. Irrespective
of pubertal status, both female age groups showed a significant increase
(p=0.033 in the pre-pubertal girls; p=0.019 in the adolescent girls) in
activation with repeated exposure to androstadienone, whereas hypothalamic
activations tended to decrease in boys toward the end of the odor stimulation.
The data for this figure was visualized using the toolbox rfxplot by Gläscher (55).
FIGURE 2 | (A,B) Show the anatomic locations of the significant
hypothalamic activations, indicated in red, in response to the chemo-signal
androstadienone in the pre-pubertal age groups. The numbers above each
sagittal plane represent the x -axis coordinates in Montreal Neurological
Institute space. All voxels within the hypothalamic region of interest,
surviving the statistical threshold of p<0.05 (FWE-corrected) are shown.
(C–E) Show the bar graphs of the corresponding group contrasts for the
first-order time-modulation regressor, indicating group differences in
sensitization to the steroid odor. (C) Displays the sex difference, i.e.,
between control girls and boys; (D) shows the non-significant sex-atypical
(i.e., female-like) and (E) indicates the significant sex-typical (i.e., male-like)
response of boys with gender dysphoria.
adolescent control girls showed a stronger hypothalamic activa-
tion compared to boys (at both developmental stages), and that this
sex difference was crucially modulated by effects of sensitization to
androstadienone.
Previous psychophysiological studies in children and adoles-
cents have shown that olfactory sensitivity to androgenic odors
differed between boys and girls during development, due to
the increased production of endogenous androgens by boys
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FIGURE 3 | (A–C) Show the anatomic locations of the significant hypothalamic
activations, indicated in red, in response to the chemo-signal androstadienone
in the adolescent age groups. The numbers above each sagittal plane
represent the x -axis coordinates in Montreal Neurological Institute space. All
voxels within the hypothalamic region of interest, surviving the statistical
threshold of p<0.05 (FWE-corrected) are shown. (D–H) Show the bar graphs
of the corresponding group contrasts. (D–E) Show the significant group
contrasts of the first-order time-modulation regressor, indicating sensitization
to the steroid odor in control girls compared with (A) control boys and (E) girls
with gender dysphoria. (F) Shows the non-significant sex-typical (female-like)
response of girls with gender dysphoria. (G) Displays the significant
female-typical response of the boys with gender dysphoria for the contrast of
the condition ON>OFF, irrespective of any effects of time; (H) shows the
non-significant male-typical response of boys with gender dysphoria.
during puberty and the assumed resulting adaptation to their
own body odors (20–23). These findings suggested that puberty
plays an important role in the development of sex differences in
the olfactory sensitivity to androstadienone (48). Therefore, we
hypothesized that the hypothalamic response in males, in contrast
to that in females, would similarly be subject to neuronal adap-
tation after repeated exposure to the steroid odor. However, our
results suggested only slight neuronal adaptation effects in boys,
their activation remained relatively stable throughout the scanning
session; instead, we found that girls showed an increase in hypo-
thalamic responsiveness during the course of the odor stimulation.
In line with the idea that androstadienone may function as a male
modulator chemo-signal, our findings thus suggest that androsta-
dienone indeed affects brain functions in females. Moreover, we
showed that the sex difference in hypothalamic activation was not
related to any hormonal or sexual maturation-related changes dur-
ing puberty. Therefore, sex differences in neural responsiveness are
probably not associated with differences in olfactory sensitivity
to androstadienone and thus, its subjectively perceived inten-
sity. Accordingly, we did not find any significant sex differences
in the reported intensity ratings of androstadienone in both the
pre-pubertal and adolescent groups.
GENDER IDENTITY AND HYPOTHALAMIC ACTIVATION
Gender dysphoria has been hypothesized to develop due to an
altered sexual differentiation of the body and the brain dur-
ing early development (30, 31). Here, we investigated a unique
data set of individuals with GD at two different developmen-
tal stages, in order to determine whether they would respond
to androstadienone in accordance with their natal sex, rather
than their experienced gender. We found that both, adolescent
girls and boys with GD showed hypothalamic activations that
reflected their experienced gender. The sex difference that we
observed in the control groups, was absent in both age groups
of boys and girls diagnosed with GD. However, pre-pubertal
girls with GD showed no differences in hypothalamic activa-
tion compared to both control boys and girls, whereas pre-
pubertal boys with GD showed significant sex-typical hypothal-
amic activations and thus, in accordance with their natal sex.
These findings thus suggest that individuals with GD possess cer-
tain functional brain characteristics, i.e., hypothalamic activation
to androstadienone, of their experienced gender and thus that
they may have undergone atypical neuronal sexual differentia-
tion. However, this can only be observed reliably in adolescents
with GD.
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Table 3 | ANOVA results showing sex-typical hypothalamic
activations, reflecting their natal sex, in individuals with GD.
Effect Zmax x y z N PFWE
GIRLS WITH GD>CTRL BOYS
Children No effects
Adolescents Gender – – – – – –
Odor 2.5 6 -9 -5 25 0.203
ON-OFF 1.7 -6 -7 -5 2 0.512
ONTM-OFFTM 2.3 -6 -9 -8 25 0.258
CTRL GIRLS>BOYS WITH GD
Children Gender 3.0 -6 -10 -6 35 0.065
Odor 2.6 3 -16 -9 27 0.168
ON-OFF 1.6 -2 -16 -6 4 0.550
ONTM-OFFTM 3.5 -6 -10 -6 126 0.013
Adolescents Gender 2.2 -2 -4 -10 5 0.336
Odor 1.5 2 -14 -12 4 0.699
ON-OFF – – – – – –
ONTM-OFFTM 1.7 6 -8 -4 7 0.504
1.6 -6 -12 -8 16 0.553
GIRLS WITH GD>BOYS WITH GD
Children No effects
Adolescents Gender – – – – – –
Odor 1.9 3 -12 -9 12 0.535
ON-OFF – – – – – –
ONTM-OFFTM 1.9 -6 -7 -11 1 0.459
Ctrl, control; GD, gender dysphoria; Zmax, z-value of peak activation voxel; x y z,
coordinates in Montreal Neurological Institute (MNI) space; N, number of cluster-
ing voxels (cluster size); FWE, family-wise error; the effects “Gender” and “Odor”
indicate omnibus F-contrasts for the factors gender and odor stimulation; “ON-
OFF” and “ONTM-OFFTM” indicate directional t-contrasts for the condition effect
and the first-order time-modulation regressor, respectively. Bold font indicates
statistically significant effects.
Girls diagnosed with GD
Pre-pubertal girls with GD did not differ in hypothalamic acti-
vation from control girls indicating that they did not show a
male-typical response. However, they also did not show a female-
typical hypothalamic activation, when compared to control boys,
indicating that they did not differ from either of the control groups.
It is possible that pre-pubertal girls with GD constitute a rather
heterogeneous group with respect to future persisting GD. It has
been shown that only about 15.8% of the childhood GD cases will
eventually lead to adult GD (49). However, women present more
often early-onset cases (50) and girls have overall higher persis-
tency rates of GD into adolescence compared to boys (51). Thus,
our finding that pre-pubertal girls with GD did not show a clear-
cut female- or male-typical response to androstadienone awaits
further confirmation in the future, when it will be known who
of our participants showed persisting GD into adolescence and
adulthood.
The comparison of adolescent female controls versus adoles-
cent girls with GD revealed very similar results as the control
group comparisons, i.e., stronger hypothalamic activations in
those subjects experiencing a female gender identity, and this effect
was mainly driven by effects over time, reflecting sensitization.
Thus, adolescent girls with GD responded remarkably like their
experienced gender (control boys). While speculative, these find-
ings fit with the idea that this group of girls with GD (who
are more homogenous in terms of future persisting GD com-
pared to the pre-pubertal groups) may have had a more male-
typical perinatal hormonal environment, resulting in the devel-
opment of certain typically male functional sex characteristics
of the brain. The hypogonadal state of adolescent girls with
GD using GnRHa at the moment of data acquisition is not
likely to account for these findings, since our results in the pre-
pubertal control groups suggest that hypothalamic responsiveness
to androstadienone is probably independent of puberty, and thus
not affected by circulating sex hormones. Furthermore, animal
studies showed that sexually dimorphic responses to volatile uri-
nary odors were not dependent on circulating sex steroids, but
rather developed under the influence of organizational effects of
sex hormones (52, 53).
It should be noted, though, that sexual orientation of the par-
ticipants with GD might present a confounding factor. Berglund
et al. (27) showed that hypothalamic responsiveness to androsta-
dienone in lesbian women was comparable to that of heterosexual
men. In the literature, the majority of natal females with GD are
reported to be gynephilic (50, 54), which was true as well for our
group of adolescent gender dysphoric girls. Therefore, it cannot
be ruled out that the resemblance in hypothalamic activation with
the control boys might be due to their shared sexual orientation
rather than their shared gender identity.
Boys diagnosed with GD
The hypothalamic response to androstadienone in the pre-
pubertal boys with GD was not significantly stronger than that
shown by the pre-pubertal control boys. Moreover, the reverse
contrast (control girls> boys with GD) revealed that pre-pubertal
control girls showed significantly stronger hypothalamic activa-
tion, implying that boys with GD responded according to their
natal sex. Again, it is likely that the younger, pre-pubertal sam-
ple of boys with GD constitutes a rather heterogeneous group in
terms of future persistence of their gender dysphoric feelings (49,
51). Therefore, they may show more variability in hypothalamic
responsiveness to androstadienone.
Adolescent boys with GD showed significantly stronger, thus
sex-atypical hypothalamic activations, compared to control boys,
although this effect was not modulated by any effects of time, thus
sensitization to androstadienone, as we did observe in the control
girls. Accordingly, the reverse comparison (control girls> boys
with GD) revealed no significant effects. The female-typical acti-
vation in adolescent boys with GD is in line with a previous
study by Berglund et al. (26), who reported that adult men with
GD differed significantly from a group of male controls in terms
of hypothalamic activation during exposure to androstadienone.
Their adult participants with GD were matched to control men
with regard to hormonal status and gynephilic sexual orientation,
whereas in our study adolescent boys with GD received GnRHa at
the moment of data acquisition and the majority of our partic-
ipants reported to have an androphilic sexual orientation. Thus,
despite differences with regard to the participants’ age, hormonal
status, and sexual orientation, the findings of both studies suggest
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that males with GD possess certain female-typical brain func-
tions, and may therefore have undergone sex-atypical early brain
development.
Some limitations of the present study should be mentioned and
may be addressed in future research. In most comparisons, the
gender differences in hypothalamic response to androstadienone
showed relatively small effect sizes. These effect sizes, in combi-
nation with relatively small group sizes (especially that of the
pre-pubertal girls with GD with N = 17), suggest that a lack of
statistical power may be related to our failure in finding any sig-
nificant effects for particularly this group. Therefore, additional
analyses in other functional and structural (e.g., gray and white
matter volumes or diffusion tensor imaging data) MRI measures,
which are in preparation, should corroborate the present prelim-
inary findings. Sexual orientation was difficult to assess in our
young groups of participants. We therefore estimated their (future)
sexual orientation by asking whether he/she had ever been in
love. However, any relationship between sexual orientation and
the response to androstadienone could not reliably be investigated
in our groups.
In summary, the present study is the first to demonstrate
that sex differences in hypothalamic activation upon smelling
the chemo-signal androstadienone are not acquired during sex-
ual maturation, under the influence of gonadal hormones dur-
ing puberty, but may be considered hard-wired responses, which
already can be observed in pre-pubertal children. Moreover,
the current study is the first to explore sex-atypical hypothala-
mic responses to androstadienone in male and female individ-
uals with GD at two different developmental stages. Our results
indeed suggest that individuals with GD possess certain functional
brain characteristics of their experienced gender and may have
undergone atypical neuronal sexual differentiation.
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